SpecialtiesQuestion

In what scenario would you choose to order a PETH over urine ETG (and vice-versa) if there is suspicion of alcohol use in a patient with chronic liver disease or cirrhosis?

Join the Discussion

Discuss the cases and questions guidelines don't cover.

Related Questions

After discharge for alcohol-associated hepatitis, what minimum frequency and type of addiction- focused contact do you aim to ensure (e.g., counseling, program participation, medication management) to meaningfully reduce early return to drinking?

In severe alcohol-associated hepatitis complicated by renal dysfunction or prolonged hospitalization, do you start medications for alcohol use disorder during the admission or defer until medical stabilization?

In severe alcohol-associated liver disease with limited documented abstinence, what prospectively measurable psychosocial signals are sufficient for you to support expedited listing (treatment engagement, insight, caregiver reliability, objective toxicology strategy), and which findings reliably predict unacceptable relapse risk in your experience?

How do you incorporate routine alcohol biomarkers (e.g., PEth) into hepatology care to support AUD recognition and ongoing monitoring without increasing shame-driven concealment, particularly in liver transplant candidates?

In alcohol-associated liver disease with comorbid depression or anxiety, how do you decide between parallel initiation of AUD treatment versus sequencing mood treatment first? What objective metrics do you use to determine when psychiatric symptoms are the primary barrier to AUD treatment engagement?

Evidence Meets Expertise

Community

Browse Specialties
Code of Conduct
AI Community Guidelines

Tools

Mednet AI
Mobile App

Company

About
Careers
Our Work
Blog

Support

FAQs
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.